For the quarter ending 2025-09-30, RMTG had -$428,559 decrease in cash & cash equivalents over the period. -$428,560 in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -4,353,741 | -2,065,825 |
| Amortization of debt discount | 518,413 | 57,864 |
| Depreciation and amortization expense | 76,078 | 106,646 |
| Change in fair value of derivative liability | -863 | -1,477 |
| Loss on extinguishment of debt | -416,155 | - |
| Preferred shares issued with debt | 0 | 401 |
| Accounts receivable | 77,330 | 14,071 |
| Prepaid expenses | -100,000 | 105,179 |
| Inventory | 50,198 | 95,573 |
| Other asset | 20,000 | 0 |
| Accounts payable and accrued liabilities | 3,186,028 | 1,573,277 |
| Cash provided (used) by operating activities | -203,731 | -540,984 |
| Purchase of property and equipment | 224,829 | 110,582 |
| Cash used by investing activities | -224,829 | -110,582 |
| Proceeds from issuance of debt | 0 | 1,100,000 |
| Cash provided by financing activities | 0 | 1,100,000 |
| Net increase in cash | -428,559 | 448,434 |
| Cash and cash equivalents at beginning of period | 1,165,820 | - |
| Cash and cash equivalents at end of period | 1,185,695 | - |
Regenerative Medical Technology Group Inc. (RMTG)
Regenerative Medical Technology Group Inc. (RMTG)